Table 2 Associations between NDRG2 mRNA and baseline variables for the 102 CLL subjects
From: NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia
| Â | Median (95% CI) | P-value |
|---|---|---|
Age (years) | ||
  ≤ 60 years | 0.0015 (0–0.0303) | 0.280 |
  > 60 years | 0.0017 (0–0.0340) | |
Gender | ||
 Male | 0.0018 (0–0.0366) | 0.194 |
 Female | 0.0009 (0–0.0193) | |
Binet stage | ||
 A | 0.0036 (0.0004–0.0428) | 0.001 |
 B/C | 0.0011 (0–0.0245) | |
Lymphocytes (×109/L) | ||
  < 50 | 0.0018 (0–0.0238) | 0.618 |
  ≥ 50 | 0.0013 (0–0.0398) | |
LDH | ||
  ≤ ULN | 0.0025 (0–0.0303) | 0.036 |
  > ULN | 0.0008 (0–0.0375) | |
β2-MG | ||
  ≤ ULN | 0.0012 (0–0.0341) | 0.539 |
  > ULN | 0.0018 (0–0.0330) | |
CD38 (n = 100) | ||
  < 30% | 0.0020 (0–0.0358) | 0.063 |
  ≥ 30% | 0.0008 (0–0.0268) | |
ZAP-70 (n = 100) | ||
  < 20% | 0.0017 (0.0002–0.0389) | 0.244 |
  ≥ 20% | 0.0020 (0–0.0274) | |
IGHV (n = 101) | ||
 Mutated | 0.0031 (0.0002–0.0303) | 0.004 |
 Unmutated | 0.0008 (0–0.0371) | |
p53aberration | ||
 No TP53 mutation or p53 deletion | 0.0027 (0.0001–0.0353) | < 0.001 |
 TP53 mutation or p53 deletion | 0.0003 (0–0.0009) | |